CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
LY2127399 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00689728
NCT00689728Phase 2Completed
CompareCT.gov

A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy

Eli Lilly and Company·interventional·Posted Jun 4, 2008·Updated Dec 6, 2018

In Brief

A Phase 2 clinical trial evaluating LY2127399 and Placebo for Arthritis, Rheumatoid. Completed, enrolled 100 participants across 45 sites in 10 countries.

Detailed Summary

The purpose of this study is to explore whether LY2127399 is effective in relieving signs and symptoms of rheumatoid arthritis (RA) in patients with a history of inadequate response or intolerance to at least 1 Tumor Necrosis Factor-Alpha (TNFα) inhibitor therapy. Examples of these TNFα inhibitor therapies that are currently on the market include Enbrel® (etanercept), Remicade® (infliximab), and Humira® (adalimumab).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesArgentina, Austria, Belgium, Brazil, Canada, Germany, Mexico, Poland, Puerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 4, 2008
Enrollment StartJun 1, 2008
Primary CompletionFeb 1, 2010
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.1 years ago

Interventions

LY2127399biological

LY2127399 will be administered as a single IV infusion over 30 minutes.

Placebodrug

Placebo will be administered as a single IV infusion over 30 minutes.